343 related articles for article (PubMed ID: 17989103)
1. Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: a pilot study.
Senthil Nayagam L; Ganguli A; Rathi M; Kohli HS; Gupta KL; Joshi K; Sakhuja V; Jha V
Nephrol Dial Transplant; 2008 Jun; 23(6):1926-30. PubMed ID: 17989103
[TBL] [Abstract][Full Text] [Related]
2. Sequential maintenance therapy with cyclosporin A and mycophenolate mofetil for sustained remission of childhood steroid-resistant nephrotic syndrome.
Gellermann J; Ehrich JH; Querfeld U
Nephrol Dial Transplant; 2012 May; 27(5):1970-8. PubMed ID: 21976740
[TBL] [Abstract][Full Text] [Related]
3. Prospective controlled study on mycophenolate mofetil and prednisolone in the treatment of membranous nephropathy with nephrotic syndrome.
Chan TM; Lin AW; Tang SC; Qian JQ; Lam MF; Ho YW; Tse KC; Chan KW; Lai KN; Tang CS
Nephrology (Carlton); 2007 Dec; 12(6):576-81. PubMed ID: 17995584
[TBL] [Abstract][Full Text] [Related]
4. Mycophenolate mofetil and prednisolone therapy in children with steroid-dependent nephrotic syndrome.
Bagga A; Hari P; Moudgil A; Jordan SC
Am J Kidney Dis; 2003 Dec; 42(6):1114-20. PubMed ID: 14655181
[TBL] [Abstract][Full Text] [Related]
5. Mycophenolate mofetil treatment for primary glomerular diseases.
Choi MJ; Eustace JA; Gimenez LF; Atta MG; Scheel PJ; Sothinathan R; Briggs WA
Kidney Int; 2002 Mar; 61(3):1098-114. PubMed ID: 11849465
[TBL] [Abstract][Full Text] [Related]
6. Combination of immunosuppressive agents in treatment of steroid-resistant minimal change disease and primary focal segmental glomerulosclerosis.
El-Reshaid K; El-Reshaid W; Madda J
Ren Fail; 2005; 27(5):523-30. PubMed ID: 16152989
[TBL] [Abstract][Full Text] [Related]
7. Mycophenolate mofetil in idiopathic membranous nephropathy: a clinical trial with comparison to a historic control group treated with cyclophosphamide.
Branten AJ; du Buf-Vereijken PW; Vervloet M; Wetzels JF
Am J Kidney Dis; 2007 Aug; 50(2):248-56. PubMed ID: 17660026
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of primary nephrotic syndrome in elderly Japanese: retrospective analysis of the Japan Renal Biopsy Registry (J-RBR).
Yokoyama H; Sugiyama H; Narita I; Saito T; Yamagata K; Nishio S; Fujimoto S; Mori N; Yuzawa Y; Okuda S; Maruyama S; Sato H; Ueda Y; Makino H; Matsuo S
Clin Exp Nephrol; 2015 Jun; 19(3):496-505. PubMed ID: 25230687
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of combined cyclosporin A and mycophenolate mofetil therapy in patients with cyclosporin-resistant focal segmental glomerulosclerosis.
Segarra Medrano A; Vila Presas J; Pou Clavé L; Majó Masferrer J; Camps Doménech J
Nefrologia; 2011; 31(3):286-91. PubMed ID: 21468162
[TBL] [Abstract][Full Text] [Related]
10. Mycophenolate mofetil treatment in primary glomerular disease: one-year follow-up in steroid dependent and resistant nephrotic syndrome.
Tasanarong A; Thitiarchakul S
J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S218-27. PubMed ID: 17044475
[TBL] [Abstract][Full Text] [Related]
11. Mycophenolate mofetil treatment for therapy-resistant glomerulopathies.
Sahin GM; Sahin S; Kantarci G; Ergin H
Nephrology (Carlton); 2007 Jun; 12(3):285-8. PubMed ID: 17498124
[TBL] [Abstract][Full Text] [Related]
12. Aggressive treatment may be needed for idiopathic membranous nephropathy with focal segmental glomerulosclerosis lesions.
Cheng P; Xie Q; Liu S; Liu X; Wang L; Hao CM
Rev Assoc Med Bras (1992); 2024; 70(4):e20230871. PubMed ID: 38716932
[TBL] [Abstract][Full Text] [Related]
13. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis.
Chan TM; Tse KC; Tang CS; Mok MY; Li FK;
J Am Soc Nephrol; 2005 Apr; 16(4):1076-84. PubMed ID: 15728784
[TBL] [Abstract][Full Text] [Related]
14. Tacrolimus therapy in adults with steroid- and cyclophosphamide-resistant nephrotic syndrome and normal or mildly reduced GFR.
Li X; Li H; Ye H; Li Q; He X; Zhang X; Chen Y; Han F; He Q; Wang H; Chen J
Am J Kidney Dis; 2009 Jul; 54(1):51-8. PubMed ID: 19406543
[TBL] [Abstract][Full Text] [Related]
15. [Mycophenolate mofetil in the treatment of primary nephrotic syndrome].
Zhao M; Chen X; Chen Y; Liu Z; Liu Y; Lu F; Zhang Y; Wang H
Zhonghua Yi Xue Za Zhi; 2001 May; 81(9):528-31. PubMed ID: 11809115
[TBL] [Abstract][Full Text] [Related]
16. Steroid resistant focal segmental glomerulosclerosis: effect of arterial hyalinosis on outcome: single center study.
Soliman AR; Maamoun H; Soliman H; Ahmed RM
Rom J Intern Med; 2021 Jun; 59(2):127-133. PubMed ID: 33565308
[No Abstract] [Full Text] [Related]
17. Use of mycophenolate mofetil in resistant membranous nephropathy.
Miller G; Zimmerman R; Radhakrishnan J; Appel G
Am J Kidney Dis; 2000 Aug; 36(2):250-6. PubMed ID: 10922302
[TBL] [Abstract][Full Text] [Related]
18. Treatment with mycophenolate mofetil and prednisolone for steroid-dependent nephrotic syndrome.
Afzal K; Bagga A; Menon S; Hari P; Jordan SC
Pediatr Nephrol; 2007 Dec; 22(12):2059-65. PubMed ID: 17938973
[TBL] [Abstract][Full Text] [Related]
19. Mycophenolate mofetil monotherapy in membranous nephropathy: a 1-year randomized controlled trial.
Dussol B; Morange S; Burtey S; Indreies M; Cassuto E; Mourad G; Villar E; Pouteil-Noble C; Karaaslan H; Sichez H; Lasseur C; Delmas Y; Nogier MB; Fathallah M; Loundou A; Mayor V; Berland Y
Am J Kidney Dis; 2008 Oct; 52(4):699-705. PubMed ID: 18585835
[TBL] [Abstract][Full Text] [Related]
20. Mycophenolate mofetil in steroid/cyclosporine-dependent/resistant nephrotic syndrome.
Mendizábal S; Zamora I; Berbel O; Sanahuja MJ; Fuentes J; Simon J
Pediatr Nephrol; 2005 Jul; 20(7):914-9. PubMed ID: 15891923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
